|
|
Volumn 12, Issue 10, 2013, Pages 725-727
|
|
PARP inhibitors bounce back
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AGO 14699;
ANTINEOPLASTIC AGENT;
BMN 673;
CO 288;
DOXORUBICIN;
INIPARIB;
NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1;
NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2;
NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;
NIRAPARIB;
OLAPARIB;
PLACEBO;
RUCAPARIB;
UNCLASSIFIED DRUG;
VELIPARIB;
BREAST CANCER;
BREAST METASTASIS;
DNA REPAIR;
DRUG APPROVAL;
DRUG INDUSTRY;
HUMAN;
OVARY CANCER;
PRIORITY JOURNAL;
REVIEW;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
CLINICAL TRIALS, PHASE III AS TOPIC;
DRUG DESIGN;
DRUG INDUSTRY;
ENZYME INHIBITORS;
FEMALE;
HUMANS;
OVARIAN NEOPLASMS;
POLY(ADP-RIBOSE) POLYMERASES;
|
|
EID: 84885012827
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4147 Document Type: Review |
|
Times cited : (30)
|
|
References (0)
|
